TDF/FTC/LPV/r

PreclinicalSmall molecule

UUniversity of Alberta

TDF/FTC/LPV/r is one of 34 small molecule programs targeting Primary Biliary Cirrhosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Biliary CirrhosisActive, not recruiting

Primary Biliary CirrhosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Primary Biliary Cirrhosis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Approved

1 2

Olumiant

Viread

Emtriva

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Retrovir

Trexall

Alnylam Pharmaceuticals

Phase 3

3 8

Actigall

AbbVie

Phase 3

2 9

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 10

Iqirvo

Ipsen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Biliary Cirrhosis1 trial

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis

Terminated·UUniversity of Alberta·N/A·NCT01614405·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TDF/FTC/LPV/r. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TDF/FTC/LPV/r compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TDF/FTC/LPV/r. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alberta company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alberta

TDF/FTC/LPV/r

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Biliary Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News